CIK 0000914475 · Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330525145
- Phone
- (858) 617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-13 | ROBERTS EIRY Chief Medical Officer | Option exercise 10b5-1 | +1,372 | 36,140 | ||
| 2025-02-13 | ROBERTS EIRY Chief Medical Officer | Option exercise · Restricted Stock Unit 10b5-1 | −2,113 | 4,227 | ||
| 2025-02-13 | ROBERTS EIRY Chief Medical Officer | Option exercise · Restricted Stock Unit 10b5-1 | −1,120 | 3,363 | ||
| 2025-02-13 | ROBERTS EIRY Chief Medical Officer | Option exercise · Restricted Stock Unit 10b5-1 | −1,372 | 4,115 | ||
| 2025-02-13 | Onyia Jude Chief Scientific Officer | Option exercise 10b5-1 | +2,717 | 18,278 | ||
| 2025-02-13 | Onyia Jude Chief Scientific Officer | Sale 10b5-1 | −1,432 | $116.83 | $167K | 16,846 |
| 2025-02-13 | Onyia Jude Chief Scientific Officer | Option exercise 10b5-1 | +2,690 | 19,536 | ||
| 2025-02-13 | Onyia Jude Chief Scientific Officer | Sale 10b5-1 | −1,447 | $116.75 | $169K | 18,089 |
| 2025-02-13 | Onyia Jude Chief Scientific Officer | Option exercise · Restricted Stock Unit 10b5-1 | −2,717 | 5,434 | ||
| 2025-02-13 | Onyia Jude Chief Scientific Officer | Option exercise · Restricted Stock Unit 10b5-1 | −2,690 | 8,070 | ||
| 2025-02-13 | Lippoldt Darin Chief Legal Officer | Option exercise 10b5-1 | +2,083 | 43,572 | ||
| 2025-02-13 | Lippoldt Darin Chief Legal Officer | Sale 10b5-1 | −1,098 | $116.76 | $128K | 42,474 |
| 2025-02-13 | Lippoldt Darin Chief Legal Officer | Option exercise 10b5-1 | +2,017 | 44,491 | ||
| 2025-02-13 | Lippoldt Darin Chief Legal Officer | Sale 10b5-1 | −1,086 | $116.75 | $127K | 43,405 |
| 2025-02-13 | Lippoldt Darin Chief Legal Officer | Option exercise · Restricted Stock Unit 10b5-1 | −2,083 | 4,166 | ||
| 2025-02-13 | Lippoldt Darin Chief Legal Officer | Option exercise · Restricted Stock Unit 10b5-1 | −2,017 | 6,053 | ||
| 2025-02-13 | Gano Kyle Chief Executive Officer | Option exercise 10b5-1 | +2,566 | 140,224 | ||
| 2025-02-13 | Gano Kyle Chief Executive Officer | Sale 10b5-1 | −1,352 | $116.84 | $158K | 138,872 |
| 2025-02-13 | Gano Kyle Chief Executive Officer | Option exercise 10b5-1 | +2,241 | 141,113 | ||
| 2025-02-13 | Gano Kyle Chief Executive Officer | Sale 10b5-1 | −1,206 | $116.86 | $141K | 139,907 |
Page 21 of 49 · 963 trades